Last10K.com

Oncobiologics, Inc. (ONS) SEC Filing 10-K Annual report for the fiscal year ending Friday, September 30, 2016

Oncobiologics, Inc.

CIK: 1649989 Ticker: ONS
Document And Entity Information - USD ($)
12 Months Ended
Sep. 30, 2016
Dec. 28, 2016
Mar. 31, 2016
Document And Entity Information [Abstract]   
Entity Registrant NameOncobiologics, Inc.  
Entity Central Index Key0001649989  
Trading Symbolons  
Entity Current Reporting StatusYes  
Entity Voluntary FilersNo  
Current Fiscal Year End Date--09-30  
Entity Filer CategorySmaller Reporting Company  
Entity Well-known Seasoned IssuerNo  
Entity Common Stock, Shares Outstanding 23,578,942 
Entity Public Float  $ 0
Document Type10-K  
Document Period End DateSep. 30, 2016  
Amendment Flagfalse  
Document Fiscal Year Focus2016  
Document Fiscal Period FocusFY  

View differences made from one year to another to evaluate Oncobiologics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Oncobiologics, Inc..

Continue

Assess how Oncobiologics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Oncobiologics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2016 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (parentheticals)
Consolidated Statements Of Cash Flows (unaudited)
Consolidated Statements Of Operations (unaudited)
Consolidated Statements Of Redeemable Preferred Stock, Common Stock, Noncontrolling Interests And Stockholders' Equity (deficit) -(unaudited)
Accrued Expenses
Accrued Expenses (details)
Accrued Expenses (tables)
Basis Of Presentation And Summary Of Significant Accounting Policies
Basis Of Presentation And Summary Of Significant Accounting Policies (detail Textuals)
Basis Of Presentation And Summary Of Significant Accounting Policies (details)
Basis Of Presentation And Summary Of Significant Accounting Policies (policies)
Basis Of Presentation And Summary Of Significant Accounting Policies (tables)
Collaboration Arrangements
Collaboration Arrangements (detail Textuals)
Commitments
Commitments (detail Textuals)
Commitments (details)
Commitments (tables)
Debt
Debt (detail Textuals)
Debt (details 1)
Debt (details)
Debt (tables)
Fair Value Measurements
Fair Value Measurements (detail Textuals)
Fair Value Measurements (details 1)
Fair Value Measurements (details 2)
Fair Value Measurements (details)
Fair Value Measurements (tables)
Income Taxes
Income Taxes (detail Textuals)
Income Taxes (details 1)
Income Taxes (details 2)
Income Taxes (details 3)
Income Taxes (details)
Income Taxes (tables)
Liquidity
Liquidity (detail Textuals)
Organization And Description Of Business (detail Textuals)
Organization And Operations
Property And Equipment
Property And Equipment (detail Textuals)
Property And Equipment (details 1)
Property And Equipment (details)
Property And Equipment (tables)
Redeemable Preferred Stock, Common Stock, Noncontrolling Interests And Stockholders' Equity (deficit)
Redeemable Preferred Stock, Common Stock, Noncontrolling Interests And Stockholders' Equity (deficit) (detail Textuals 1)
Redeemable Preferred Stock, Common Stock, Noncontrolling Interests And Stockholders' Equity (deficit) (detail Textuals)
Related-party Transactions
Related-party Transactions (detail Textuals)
Stock Based Compensation (detail Textuals 1)
Stock Based Compensation (detail Textuals 2)
Stock Based Compensation (detail Textuals 3)
Stock Based Compensation (detail Textuals)
Stock Based Compensation (details 1)
Stock Based Compensation (details 2)
Stock Based Compensation (details 3)
Stock Based Compensation (details 4)
Stock Based Compensation (details)
Stock-based Compensation
Stock-based Compensation (tables)
Stockholder Notes
Stockholder Notes (detail Textuals)
Stockholder Notes (details)
Stockholder Notes (tables)
Subsequent Events
Subsequent Events (detail Textuals)

Material Contracts, Statements, Certifications & more

Oncobiologics, Inc. provided additional information to their SEC Filing as exhibits

Ticker: ONS
CIK: 1649989
Form Type: 10-K Annual Report
Accession Number: 0001571049-16-020882
Submitted to the SEC: Thu Dec 29 2016 4:17:10 PM EST
Accepted by the SEC: Thu Dec 29 2016
Period: Friday, September 30, 2016
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/ons/0001571049-16-020882.htm